Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amatuximab - Eisai

Drug Profile

Amatuximab - Eisai

Alternative Names: Anti-mesothelin monoclonal antibody; MORAb-009; MORAB-009-006

Latest Information Update: 13 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Eisai Co Ltd; Morphotek
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Megakaryocyte potentiating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mesothelioma
  • No development reported Pancreatic cancer; Solid tumours

Most Recent Events

  • 13 Mar 2019 Amatuximab is still in phase II trials for Mesothelioma in Australia, Canada, France, Germany, Italy, Netherlands, Spain, USA, United Kingdom
  • 30 Nov 2018 Morphotek terminates phase II trial due to business reasons in Mesothelioma (Combination therapy, Unresectable disease) in Australia, Canada, England, France, Germany, Italy, Scotland, Spain, United Kingdom, USA (NCT02357147)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top